Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
OrtopediaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Annals of the rheumatic diseases
- Publicado em
- 14 jun 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
Celia Aj Michielsens, Nathan den Broeder, Frank Hj van den Hoogen, Eline A M Mahler, Steven Teerenstra, Désirée van der Heijde, Lise M Verhoef, Alfons A den Broeder
Descritores MeSH
- Arthritis, Psoriatic
- Axial Spondyloarthritis
- Antirheumatic Agents
- Spondylarthritis
- Treatment Outcome
- Humans
- Drug Tapering
- Bayes Theorem
- Tumor Necrosis Factor Inhibitors
Veja também
Estudos relacionados
- Discontinuing or Tapering Biologic or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: A Systematic Literature Review
- Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review
- Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis
- Effects of disease-modifying anti-rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: a systematic review and meta-analysis